In-Situ Forming Gel (UTHSC)
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of Tennessee Health Sciences Center
Details
- API: Levonorgestrel
- Target: Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: PLA, PLGA
- Regimen: 1 Injection/6 Months
- MPT: Not Potential MPT
Product Status
Positive results in 2017 but no evidence of further development
History
2017 animal study results suggest that UTHSC's gel may be able to be injected through a 21 G or smaller needle and reliably suppress ovulation for up to 7 months. A number of other in situ forming gels, including those developed by MedinCell and Kydes, are under development simultaneously. No indication of continued pre-clinical research for UTHSC's concept.